Payment overview · 2025
General Payments
$326.19
16 reported records · 7 companies
Healthcare provider profile · identity verified
Jade Bryant, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PUEBLO, CO · NPI 1154861995
Verified facts
What the public records show
CMS Open Payments records show Jade Bryant, FNP-BC received $326.19 in general payments during 2025 across 16 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $88.39 | 27.1% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.57 | 19.5% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $41.68 | 12.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.83 | 12.5% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $38.06 | 11.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.33 | 11.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.33 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.19 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $88.39 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.63 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $41.68 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.83 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.83 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 227 | 22 |
| Omeprazole | Omeprazole | 136 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 111 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 21 |
| Gabapentin | Gabapentin | 96 | 16 |
| Atorvastatin Calcium | Atorvastatin Calcium | 95 | 24 |
| Synthroid | Levothyroxine Sodium | 90 | 17 |
| Bumetanide | Bumetanide | 87 | 16 |
| Baclofen | Baclofen | 82 | suppressed |
| Buprenorphine | Buprenorphine | 80 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 11 |
| Ondansetron Odt | Ondansetron | 76 | 15 |
| Trazodone Hcl | Trazodone Hcl | 74 | 13 |
| Buspirone Hcl | Buspirone Hcl | 65 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 65 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | suppressed |
| Linzess | Linaclotide | 63 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 62 | 12 |
| Acyclovir | Acyclovir | 61 | 16 |
| Losartan Potassium | Losartan Potassium | 61 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 59 | suppressed |
| Ozempic | Semaglutide | 58 | suppressed |
| Ibuprofen | Ibuprofen | 57 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 26 |
| Lorazepam | Lorazepam | 56 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 55 | suppressed |
| Prednisone | Prednisone | 53 | 18 |
| Pregabalin | Pregabalin | 53 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Estradiol | Estradiol | 49 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | suppressed |
| Metformin Hcl | Metformin Hcl | 48 | 11 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 44 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Lisinopril | Lisinopril | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Savella | Milnacipran Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 18 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Reyvow | Lasmiditan Succinate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $326.19 · 16 records | Otsuka America Pharmaceutical, Inc. | Auvelity, Cologuard Collection Kit, DUPIXENT, JOURNAVX, Ozempic, REXULTI, Rybelsus, Symbravo, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error